by | Jun 26, 2024 | Publications
Expert Rev Hematol. 2024 Jun 26:1-18. doi: 10.1080/17474086.2024.2370552. Online ahead of print. ABSTRACT INTRODUCTION: Chimeric Antigen Receptor (CAR) T-cells and Bispecific Antibodies (BsAb) are the leading platforms for redirecting the immune system against cells...
by | Jun 26, 2024 | Publications
Iran J Public Health. 2024 Mar;53(3):568-576. doi: 10.18502/ijph.v53i3.15137. ABSTRACT Multiple Myeloma (MM) is a neoplastic hematologic disorder caused by the excessive proliferation of plasma cells and leads to bone lesions, anemia, and kidney failure. No definite...
by | Jun 26, 2024 | Publications
Front Oncol. 2024 Jun 11;14:1365460. doi: 10.3389/fonc.2024.1365460. eCollection 2024. ABSTRACT BACKGROUND: Multiple myeloma (MM) exhibits considerable heterogeneity in treatment responses and survival rates, even when standardized care is administered. Ongoing...
by | Jun 26, 2024 | Publications
South Asian J Cancer. 2024 Feb 12;13(2):126-131. doi: 10.1055/s-0043-1761441. eCollection 2024 Apr. ABSTRACT Karuna JhaBackground Multiple myeloma is a cytogenetically heterogeneous, evolving, and incurable disease. Differences in prevalence of myeloma already exist...
by | Jun 26, 2024 | Publications
J Blood Med. 2024 Jun 21;15:285-290. doi: 10.2147/JBM.S468921. eCollection 2024. ABSTRACT Immune checkpoint inhibitor-related thrombocytopenia (irTCP) is a relatively rare immune-related adverse event (irAE); however, overall survival may worsen when it occurs....
by | Jun 26, 2024 | Publications
Pharmacoeconomics. 2024 Jun 25. doi: 10.1007/s40273-024-01399-3. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: Multiple myeloma is a rare incurable hematological cancer in which most patients relapse or become refractory to treatment. This systematic...
